Evidence does not firmly support it for typical MS. Unproven therapy competes with proven disease-modifying drugs that demonstrably slow progression, and carries infection and immune-reconstitution risks. Patients with access to modern DMTs should use those first. Stem cells may be considered within regulated academic trials, or if disease is refractory to all approved therapies — otherwise the risk-benefit balance is unfavourable.
Multiple sclerosis arises from immune-mediated attack on myelin and oligodendrocytes in the central nervous system, causing demyelination and axonal loss. Stem-cell strategies target both immune dysregulation and repair: placental mesenchymal stem cells are studied for their capacity to calm autoreactive immune cells and secrete neuroprotective factors, while neurogenic cells are explored for remyelination and axonal support. Preclinical work suggests stem cells migrate toward lesions and release anti-inflammatory mediators. Trials have enrolled relapsing-remitting and progressive forms, but the mechanism of any benefit is incompletely characterised, and no approach yet reverses established disability or halts long-term progression in humans.
我是候选人吗？ → · Multiple Sclerosis: full overview → · 多发性硬化症成本 → · Cost →
由 StemCellAtlas 的编辑团队进行医学审查，与Kiian Nadiia, MD, PhD (Paediatric Neurologist · Medical Director, CSM Clinic Network · 12+ yrs in Autism Spectrum Disorders) 合作诊所 Stem Plus（索菲亚）的，根据 ISSCR、FDA 和 EMA 指南。 Educational information, not medical advice; figures indicative.
位于欧盟核心的 GMP 认证再生医学诊所——费用 3,000–8,000 欧元起，仅为美国或德国价格的一小部分。为来自 50 多个国家的国际患者提供个性化方案。
免费医疗评估